Peptidomimetic inhibitors of post-proline cleaving enzymes
Disclosed are inhibitors of post-proline cleavage enzymes, such as inhibitors of dipeptidyl peptidase IV, as well as pharmaceutical compositions thereof, and methods for using such inhibitors. In particular, the inhibitors are improved over those in the prior art by selection of particular classes of side chains in the P1 and/or P2 position of the inhibitor. The inhibitors can have a better therapeutic index, owing in part to reduced toxicity and/or improved specificity for the targeted protease.
1. A pharmaceutical composition, comprising a protease inhibitor represented by Formula I:
or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier; wherein the pharmaceutical composition is formulated as an oral dosage form or an intravenous dosage form; and the composition is co-formulated with, or co-packaged with, insulin and/or an insulinotropic agent.
2. The pharmaceutical composition of claim 1 , wherein the pharmaceutically acceptable carrier is selected from the group consisting of sugars, starches, cellulose, powdered tragacanth, malt, gelatin, talc, excipients, oils, glycols, polyols, esters, agar, buffering agents, alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethyl alcohol, and phosphate buffer solutions.
3. The pharmaceutical composition of claim 1 , wherein the composition is in a solid dosage form.
4. The pharmaceutical composition of claim 3 , wherein the composition is in the form of a tablet or capsule.
5. The pharmaceutical composition of claim 4 , wherein the composition is in the form of a coated tablet.
6. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated as an oral dosage form.
7. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated as an intravenous dosage form.
8. A pharmaceutical composition, comprising a protease inhibitor represented by Formula I:
or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier; wherein the pharmaceutical composition is formulated as an oral dosage form or an intravenous dosage form; and the composition is co-formulated with, or co-packaged with, an MI receptor antagonist, a prolactin inhibitor, an agent acting on the ATP-dependent potassium channel of β-cells, metformin, and/or a glucosidase inhibitor.
9. A packaged pharmaceutical, comprising a pharmaceutical composition of claim 1 ; and instructions, written and/or pictorial, describing the therapeutic use of the composition.
10. A packaged pharmaceutical, comprising a pharmaceutical composition of claim 8 ; and instructions, written and/or pictorial, describing the therapeutic use of the composition.
11. The pharmaceutical composition of claim 8 , wherein the pharmaceutically acceptable carrier is selected from the group consisting of sugars, starches, cellulose, powdered tragacanth, malt, gelatin, talc, excipients, oils, glycols, polyols, esters, agar, buffering agents, alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethyl alcohol, and phosphate buffer solutions.
12. The pharmaceutical composition of claim 8 , wherein the composition is in a solid dosage form.
13. The pharmaceutical composition of claim 12 , wherein the composition is in the form of a tablet or capsule.
14. The pharmaceutical composition of claim 13 , wherein the composition is in the form of a coated tablet.
15. The pharmaceutical composition of claim 8 , wherein the pharmaceutical composition is formulated as an oral dosage form.
16. The pharmaceutical composition of claim 8 , wherein the pharmaceutical composition is formulated as an intravenous dosage form.